A Single Dose of a DNA Vaccine Encoding Apa Coencapsulated with 6,6'-Trehalose Dimycolate in Microspheres Confers Long-Term Protection against Tuberculosis in Mycobacterium bovis BCG-Primed Mice

Dyego Carlétti,a Denise Morais da Fonseca,a Ana Flávia Gembre,a Ana Paula Masson,b Lívia Weijenborg Campos,b Luciana C. C. Leite,c Andréa Rodrigues Pires,d Joseli Lannes-Vieira,a Célio Lopes Silva,b Vânia Luiza Deperon Bonato,b Cynthia Horna

Laboratory of Immunology and Immunoanalytics, Evandro Chagas Clinic Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil; Center of Biotecnology, Butantan Institute, São Paulo, Brazil; Fonte Medicina Diagnóstica, Niterói, Rio de Janeiro, Brazil; Laboratory of Biology of the Interactions, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil

*Mycobacterium bovis* BCG prime DNA (Mycobacterium tuberculosis genes)-booster vaccinations have been shown to induce greater protection against tuberculosis (TB) than BCG alone. This heterologous prime-boost strategy is perhaps the most realistic vaccination for the future of TB infection control, especially in countries where TB is endemic. Moreover, a prime-boost regimen using biodegradable microspheres seems to be a promising immunization to stimulate a long-lasting immune response. The alanine proline antigen (Apa) is a highly immunogenic glycoprotein secreted by *M. tuberculosis*. This study investigated the immune protection of Apa DNA vaccine against intratracheal *M. tuberculosis* challenge in mice on the basis of a heterologous prime-boost regimen. BALB/c mice were subcutaneously primed with BCG and intramuscularly boosted with a single dose of plasmid carrying *apa* and 6,6'-trehalose dimycolate (TDM) adjuvant, coencapsulated in microspheres (BCG-APA), and were evaluated 30 and 70 days after challenge. This prime-boost strategy (BCG-APA) resulted in a significant reduction in the bacterial load in the lungs, thus leading to better preservation of the lung parenchyma, 70 days postinfection compared to BCG vaccinated mice. The profound effect of this heterologous prime-boost regimen in the experimental model supports its development as a feasible strategy for prevention of TB.

Tuberculosis (TB) is still one of the leading causes of death from a single infectious agent, causing 1.6 million deaths each year, mostly in developing countries (1, 2). Preventive efforts to control spread of TB in various parts of the world rely on the use of *Mycobacterium bovis* bacillus Calmette-Guérin (BCG) vaccine. Over 90% of children are immunized with BCG annually in most developing countries, making it the most widely used human vaccine. This vaccine offers protection against severe manifestations of childhood TB, including meningeal and miliary TB. Moreover, application of the BCG vaccine has considerably reduced the incidence of infant TB in areas where TB is endemic (3, 4, 5). However, its protective effect decreases with advancing age, and it is insufficient to control pulmonary TB, the most frequent occurrence of the disease, in adults. Heterologous prime-boost vaccines are proposed to enhance specific immunity primed by childhood BCG vaccination (6) and are one of the best candidates for novel TB vaccines. Specifically, DNA-based vaccines could be a good choice for improving BCG efficacy because they can stimulate both humoral and cell-mediated immunity in experimental TB models (7).

Antigens present in the mycobacterial culture filtrate (CF) are inducers of protective immunity against *Mycobacterium tuberculosis* challenge in mice (8, 9, 10), guinea pigs (11, 12), and nonhuman primates (13). Alanine proline antigen (Apa) is a major immunodominant antigen secreted by the *M. tuberculosis* complex (14, 15). This glycoprotein is a fibronectin attachment protein (FAP) and can mediate mycobacterial binding to host cells as a potential adhesive (16). Apa was selected based on its ability to be recognized by lymphocytes and by antibodies raised in guinea pigs immunized with living mycobacteria (17). This antigen has been previously shown to be highly antigenic in humans, in *vivo* (18, 19). Additionally, an Apa-encoding DNA vaccine (Apa DNA) induces strong Th1 and Th2 responses and is capable of activating significant protective responses in mice (20) and guinea pigs (18).

To further improve the effectiveness of subunit vaccines, adjuvants can be introduced in the vaccine formulation. 6,6'-Trehalose dimycolate (TDM) is present in *M. tuberculosis* cell walls and acts as a potent immunomodulator, preferentially inducing Th1 responses, thus making it an interesting adjuvant for TB vaccines (21). Combined with delivery systems such as microspheres, antigens (DNA, proteins, or peptides) can be encapsulated and protected from harsh conditions. The microparticles can be coencapsulated with or without immune stimulants and can be administered by different routes. Moreover, microspheres do not induce the toxicity that is generally associated with adjuvants (22, 23, 24). The choice of an appropriate adjuvant formulation and delivery system is crucial in obtaining optimal vaccine stability and effectiveness (25).

In this study, we investigated the immune protection against intratracheal *M. tuberculosis* challenge by priming with BCG and boosting with a single dose of Apa DNA vaccine, containing TDM...
adjuvant, coencapsulated in biodegradable poly(β,ε-lactide-co-glycolic acid) (PLGA) microspheres, and compared the findings with those obtained with BCG-vaccinated mice.

**MATERIALS AND METHODS**

**Animals.** Specific-pathogen-free female BALB/c mice 6 to 8 weeks of age were purchased from the breeding facility of Oswaldo Cruz Foundation (Fiocruz) and University of São Paulo (USP) at Ribeirão Preto School of Medicine, Brazil. The mice were maintained under barrier conditions in a biosafety level 3 (BSL3) facility, and they received free access to food and sterile water throughout the study period. The research protocol was reviewed and approved by and conducted according to the institutional ethical guidelines of Fiocruz (CEUA L-013/05) and USP (CETEA 05/2010).

**Bacteria.** The H37Rv strain of *M. tuberculosis* (American Type Culture Collection, Manassas, VA) was grown in 7H9 Middlebrook broth (Difco Laboratories, Detroit, MI) at 37°C for 7 days and used as previously described (26, 27). The BCG Moreau vaccine was donated by Ataulpho de Paiva Foundation (Rio de Janeiro, Brazil) and was prepared according to its instructions. Briefly, lyophilized BCG Moreau vaccine was resuspended in vaccine diluent (0.9% saline) provided by the supplier, and this suspension (5 × 10^6 CFU) was used for vaccination of mice.

**Plasmid construction.** An LB liquid medium ( Gibco BRL, Gaithersburg, MD) containing ampicillin (100 μg/ml) was used to culture *Escherichia coli* DH5α that was transformed with either empty pVAX1 plasmid (Invitrogen, Carlsbad, CA) or plasmid containing apa (pVAXapa). The apa gene without its signal sequence was cloned by PCR from pAG831 (11) using the following primers: F 5'-TAG GAA TAC GGG GCG GAG CCA CCG CC-3' and R 5'-TAG ATC CGG TCA GGC CGG TAA GGT CCG-3'. Italic and underlined sequences indicate EcoRI and XhoI (Gibco BRL, Gaithersburg, MD) restriction sites, respectively. The amplified fragment was subcloned into pGEM-T Easy (Promega Corp., Madison, WI) and further cloned into pVAX1 using EcoRI and XhoI restriction sites. The consensus ACC Kozak sequence for vertebrate mRNAs was added before the ATG start codon. The DNA sequence was analyzed and confirmed with enzyme digestion and an ABI Prism DNA sequencer (PE Applied Biosystems, Foster City, CA). Plasmids were purified using the Endofree Plasmid Giga kit (Qiagen Inc., Chatsworth, CA). Furthermore, endotoxin levels were measured using the *Limulus* amoebocyte lysate QCL-1000 kit (BioWhittaker, Walkersville, MD), and no endotoxin was detected.

**Antigen expression in transfected mammalian cells.** *In vitro* expression of Apa protein was analyzed in BHK-21 (baby hamster kidney) cells by using Lipofectamine (Life technologies). Expression was characterized by Western blotting of total extracts of BHK-21 cells 1 day after transfection by using Lipofectamine (Life technologies). Expression was characterized by Western blotting of total extracts of BHK-21 cells 1 day after transfection with Lipofectamine (Life technologies). Expression was characterized by Western blotting of total extracts of BHK-21 cells 1 day after transfection with Lipofectamine (Life technologies). Expression was characterized by Western blotting of total extracts of BHK-21 cells 1 day after transfection with Lipofectamine (Life technologies).

**Preparation of microspheres and plasmid encapsulation.** Microspheres were obtained by the double emulsion/solvent evaporation technique. Briefly, 30 ml of dichloromethane solution containing 400 mg of polymer PLGA (50:50; Resomer from Boehringer Ingelheim, Ingelheim, Germany) and 0.5 mg of TDM (Sigma, St. Louis, MO) was emulsified with 0.3 ml of an inner aqueous phase containing 5 mg of DNA (pVAX or pVAXapa) using a T25 Ultra-Turrax homogenizer (IKA Labortechnik, Germany) to produce a primary water-in-oil emulsion. This emulsion was then mixed with 100 ml of an external aqueous phase containing 1 to 3% polyvinyl alcohol (Mowiol 40-88; Aldrich Chemicals, Wanke, WI) as a surfactant to form a stable water-in-oil emulsion. The mixture was stirred for 6 h with an RW20 IKA homogenizer to evaporate the solvent. Microspheres were collected and washed 3 times with sterile water; then they were freeze-dried and stored at 4°C until use. Plasmid encapsulation efficiency was determined as described by Diwan and Park (29, 30). Briefly, 10 mg of microspheres was dissolved in 1 ml of acetonitrile. After centrifugation, the precipitated plasmid was pelleted down and supernatant containing polymer was discarded. The pellet was redispersed in phosphate-buffered saline (PBS) (50 mM, pH 7.4) and the samples (in triplicate) were centrifuged again. The supernatant was preserved and the residue was further dissolved in 0.1 N NaOH. The plasmid in aqueous and alkaline extractions was estimated using a NanoDrop ND-1000 (Thermo).

**Culture filtrate antigens.** The CF was kindly donated by Gilles Marchal of Institut Pasteur, Paris, France. It was prepared using an *M. tuberculosis* H37Rv 15-day culture, as previously described (15).

**Immunization and *M. tuberculosis* infection.** BALB/c mice were separated into 5 experimental groups: (i) PBS (received saline, nonvaccinated and noninfected), (ii) BCG (received 1 dose of BCG), (iii) BCG-PVAX (received prime BCG-boost pVAX-TDM-Me), (iv) BCA-PAPA (received prime BCG-boost pVAXapa-TDM-Me), and (v) TB (nonvaccinated and infected with *M. tuberculosis* H37Rv). Immunizations were performed according to a heterologous schedule (see below). The PBS group received 50 μl of saline in each quadriceps subcutaneously (s.c.) and intramuscularly (i.m.) in 2 doses, and mice were not infected. The BCG group received a single vaccination with 5 × 10^7 BCG Moreau bacilli and 1 dose of saline, which were administered s.c. For heterologous prime-boost vaccination schedules, mice were primed with 5 × 10^7 BCG Moreau bacilli s.c. and boosted i.m. after 30 days with 100 μg of pVAX-TDM-Me (BCG-PVAX) or pVAXapa-TDM-Me (BCG-APA) formulation. For the TB control group, mice were injected with 50 μl of saline in each quadriceps s.c. and in 2 doses i.m. Thirty days after the last immunization, mice were anesthetized with 2,2,2-tribromoethanol (Acros) by intraperitoneal administration. The trachea was exposed and inoculated with 1 × 10^6 viable bacilli of the *M. tuberculosis* H37Rv strain (ATCC 27924). The incision was sutured with sterile silk. Thirty and 70 days after infection (corresponding to the initial and chronic phases of infection, respectively), mice were euthanized for evaluation of the protective immune response. The microsphere formulations consisted of 30 μg of plasmidial DNA (pVAXapa or pVAX) in TDM-loaded PLGA 50:50 microspheres. All procedures were performed in a BSL3 room facility in the University of São Paulo at the Ribeirão Preto School of Medicine.

**CFU determination.** The right lower and middle lobes of lungs were digested using Listeria Blendzyme 2 (Roche, Indianapolis, IN) diluted (0 to 5 μg/ml) in incomplete RPMI 1640 medium (Sigma). Spleens were placed in a petri dish containing incomplete RPMI 1640 medium and then fragmented with the aid of anatomical sterile forceps. Serial dilutions of the digested lungs and macerated spleens were plated on 7H11 Middlebrook agar medium (Difco Laboratories, Detroit, MI) and used for the CFU assay as previously described (25, 26). Colonies were counted after 28 days of incubation at 37°C.

**Histopathological analysis.** The right upper lobes of the lungs were fixed in 10% formalin, embedded in paraffin blocks, prepared routinely, and then sectioned for evaluation by light microscopy. For the histopathological analyses, 5-μm-thick sections were stained with hematoxylin and eosin.

The slides from each of the mouse groups were examined in a blind study by a pathologist, to establish the pattern and extent of the histological changes. A grade was established on the basis of the most severely inflamed section on each slide. After the slides were surveyed to identify the maximal response for each category, which was designated 4+ (intense/severe), additional slides representing intermediate/moderate, low, and very low responses were designated 3+, 2+, and 1+, respectively. The absence of response was designated by a minus sign (Table 1). The results shown in Table 1 are for one representative out of 3 independent experiments.

**Statistical analysis.** Assessment of the experiments and statistical analysis were performed by using analysis of variance (ANOVA) and the Tukey test to determine the difference between the experiment group and the control groups. The data are expressed as means ± standard devia-
TABLE 1 Qualitative histopathological analysis

| Group and infection time (days) | Degree of parenchymal damage | Presence of granulomas | Infiltration of macrophages (other cells) | Infiltration of lymphocytes | Degree of inflammation |
|-------------------------------|-----------------------------|------------------------|------------------------------------------|-----------------------------|-----------------------|
| PBS 30                        | −                           | −                      | −                                        | −                           | −                     |
| 70                            | −                           | −                      | −                                        | −                           | −                     |
| TB 30                         | +++                         | +++                    | +++ (foam cells +++)                     | +++                         | +++                  |
| 70                            | +++/+++                     | +                      | +++ (giant cells +; foam cells +)        | +++                         | +++                  |
| BCG 30                        | +                           | +                      | + (giant cells +; foam cells +)          | +                           | +                    |
| 70                            | +/+++                      | +                      | + (giant cells +; foam cells +)          | +                           | ++                   |
| BCG-PVAX 30                   | +                           | +                      | + (foam cells +)                         | +                           | +                    |
| 70                            | +                          | +                      | + (giant cells + foam cells +)           | +                           | ++/+++               |
| BCG-APA 30                    | +                           | +                      | + (foam cells +)                         | +                           | +                    |
| 70                            | +                          | +                      | + (foam cells +)                         | +                           | +                    |

*a Mice (n = 5) were vaccinated with BCG, BCG-pVAX-TDM-Me, or BCG-pVAXapa-TDM-Me, as described in the legend to Fig. 3. Thirty days after the last immunization, we performed an intratracheal challenge with M. tuberculosis, and at 30 and 70 days after infection, the lungs were collected and processed for histopathological analysis. The symbols indicate the absence (−) or the very low (+), low (++), moderate (+++), or intense (++++) presence of each parameter evaluated. There were rare (+), some (++), many (+++), or numerous (++++) giant cells and foam cells. The results of one representative experiment out of three independent experiments are shown.

RESULTS

Plasmid construction and expression of Apa antigen. Apa DNA lacking the signal sequence was cloned by PCR from pAG831 (20). The amplified fragment was subcloned into pGEM-T Easy and further cloned into pVAX1 using EcoRI and XhoI sites and transformed into competent E. coli DH5α cells. The recombinant plasmid was identified by enzyme digestion on agarose gel stained with ethidium bromide. Figure 1A shows the 900-bp fragment that corresponds to apa and the 3,054-bp fragment that corresponds to the pVAX plasmid (Fig. 1A, lane 3) and pVAX digested by XhoI (Fig. 1A, lane 2).

BHK-21 cells were transfected with pVAX-apa. Total protein extract was obtained from transfected cells, and the presence of Apa in the extract was confirmed by Western blotting using an Apa-specific polyclonal antibody (Fig. 1B). The expression of Apa was confirmed by the presence of a band of 47 kDa, the expected size of the Apa protein (Fig. 1B, lane 3). Total protein extracts from BHK-21 cells transfected with plasmid pVAX (Fig. 1B, lane 2) and from untransfected controls (Fig. 1B, lane 1) did not express Apa protein, as expected.

The heterologous prime (BCG)-boost (pVAXapa-TDM-Me) regimen protects mice against M. tuberculosis infection. To improve BCG protection and evaluate a heterologous immunization schedule (Fig. 2A) using the pVAXapa-TDM-Me vaccine, mice were challenged with M. tuberculosis. At 30 (Fig. 2B) and 70 (Fig. 2C) days after infection, which correspond to the initial and chronic phases of infection, respectively, the BCG and prime-boost groups showed significant reduction in the bacterial loads in lungs compared with the TB group (30 days, P < 0.05; 70 days, P < 0.001).

Most importantly, 70 days postinfection, the strongest protective effect was seen in BCG-APA-vaccinated mice, with a significant inhibition of the growth of M. tuberculosis in the lungs compared with that in mice vaccinated with BCG alone (P < 0.005) or with BCG-pVAX (P < 0.05) (Fig. 2C). The BCG-APA group (4.6 logs) exhibited a reduction in the bacterial load which was nearly 1 order of magnitude lower than that of the BCG (5.4 logs) and BCG-PVAX (5.3 logs) groups, as well as an important reduction of approximately 2.0 logs compared with the TB group (6.6 logs).

Evaluation of the extrapulmonary protective immune response indicated that either heterologous immunization or BCG alone was effective in controlling the bacterial growth in the spleen. In both the early (Fig. 2D) and chronic (Fig. 2E) phases of experimental infection, all groups of immunized animals (BCG, BCG-PVAX, and BCG-APA) exhibited a reduction in bacterial growth of about 1 log compared to the TB infection control group (P < 0.005).

Histological evaluation of the lung specimens from the PBS control mice showed no pathological changes, with well-preserved lung parenchyma, clearly defined alveolar spaces, and no inflammatory cells in the tissue and normal lumen (Fig. 3A and B). In contrast, evaluation of the lung specimens from nonimmunized and infected mice (TB group) showed moderate impairment of the lung parenchyma and moderate inflammation with numerous granulomas 30 days after infection (Fig. 3C and Table 1). These granulomas were formed by many foam cells in their central regions. In addition, intense interstitial chronic inflammatory infiltrates were observed mostly in the peribronchiolar regions. This inflammatory infiltrate was accompanied by diffuse thickening of the alveolar walls and reductions in air space. By the later stage of infection, i.e., at 70 days, severe lung injury was diagnosed on the basis of the presence of intense inflammatory infiltrates, represented by multiple granulomas with many foam...
Infection by M. tuberculosis is a significant global health issue, and the BCG vaccine is widely used to prevent tuberculosis. Despite its widespread use, BCG has limitations in its protective efficacy, particularly in adolescents and adults. In an effort to improve BCG vaccine efficacy, a DNA vaccine expressing the Apa antigen, a highly immunogenic protein from M. tuberculosis, was developed and evaluated in a heterologous prime-boost regimen.

**Materials and Methods**

In this study, we administered single s.c. doses of BCG and a single i.m. dose of Apa DNA vaccine (pVAX-apa) to mice. We used a novel boost vaccine strategy, TDM-Me, to enhance protective immunity. The DNA vaccine was constructed using the XhoI and EcoRI restriction enzymes, and a Western blot analysis confirmed the expression of Apa protein in transfected BHK-21 cells.

**Results**

Compared to BCG alone, mice immunized with the Apa DNA vaccine showed a significant reduction in bacterial loads in the lung tissue. Moreover, these mice exhibited fewer foam and giant cells compared to BCG-immunized mice. In the BCG-PVAX group, better preservation of lung parenchyma was observed than in the BCG group. The majority of specimens from these mice exhibited fewer lymphocytic inflammatory infiltrates in the alveolar walls, and the lung parenchyma was better preserved compared to the other immunized groups.

**Discussion**

Many studies have shown that using BCG as a prime combined with a novel boost vaccine is more efficacious than BCG alone. However, revaccination with BCG in humans does not confer additional protection and, in some cases, may be deleterious to protection against TB. Therefore, the development of a new vaccine capable of promoting immunity in individuals who have already received the BCG vaccine would be very beneficial.

As reported previously, the order of prime-boost vaccination may not be critical for enhancing protection against experimental TB. Priming but not boosting with a DNA vaccine could also increase the survival time of BCG-vaccinated mice against challenge with M. tuberculosis. This vaccination strategy is often assessed by CFU counting and pathology score, but long-term survival is not always evaluated. Therefore, there is still no consensus in the order of prime-boost vaccination, and the improvement of the BCG vaccine merits further investigation.

Previous studies have shown that plasmids with *apa*-induced humoral and cell-mediated immunity provided significant protection against TB in mice and guinea pigs. Immunization with 3 doses of *apa* was shown to be highly immunogenic in a murine model. Recently, among the nine M. tuberculosis recombinant proteins evaluated, the Apa antigen was found to be highly antigenic following BCG vaccination. Our data on heterologous prime-boost immunization also confirmed this immunogenicity induced by Apa, after an intratracheal M.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (Nos. 31570093 and 81371822) and the Shandong Provincial Natural Science Foundation (No. ZR2019BF009). The authors declare no conflicts of interest.
tuberculosis infection, and showed that this immunization lasts longer than the one conferred by BCG vaccination alone.

The importance of the preservation of lung morphology along with bacterial clearance has been described previously (38, 39). Although some TB vaccines show highly prospective clearance of the bacillus, they may induce an exacerbated inflammatory response that culminates with lung necrosis (39). On the other hand, it was also reported that some other vaccines do not cause this damage but are ineffective in reducing the bacterial load to levels comparable with that induced by BCG (40). In addition, our

**FIG 2** Protection against experimental TB conferred by the different vaccination regimens. (A) The time points for immunizations, infection, and sample collection are shown. Asterisks indicate the days on which mice were infected. BALB/c mice were immunized s.c. with a single dose of BCG (5 × 10^5 CFU; BCG group) or with one dose of BCG administered s.c. followed by one dose of pVAX-TDM-Me (BCG-PVAX) or pVAXapa-TDM-Me (BCG-APA) administered i.m. after 30 days. Thirty days after vaccination, mice were challenged intratracheally with a virulent strain of *M. tuberculosis* (1 × 10^5 CFU). At 30 or 70 days after infection, the lungs (B and C) and spleens (D and E) were processed to determine bacterial loads by counting the CFU. The bacterial load is expressed as log10 CFU/g of lung and spleen, derived from the means ± SDs of serial dilutions individually counted for each group. *P* values indicating statistically significant differences among the groups are displayed in the representative graphs. *, *P* < 0.05 versus nonimmunized infected mice (TB group) at 30 days postinfection. The following symbols indicate significance at 70 days postinfection: *, *P* < 0.001 versus the TB group; X, *P* < 0.05 versus the BCG-PVAX group; and †, *P* < 0.005 versus the BGG-vaccinated group. Results of one representative experiment out of three independent experiments are shown. (Three experiments were conducted with various numbers of animals in each group, with a total of 9 to 19 mice in the 3 experiments.)
FIG 3  Histopathology of lungs from immunized mice at 30 and 70 days after *M. tuberculosis* infection. BALB/c mice (*n* = 5) were immunized s.c. with a single dose of BCG (5 × 10⁵ CFU; BCG group) or one dose of BCG administered s.c., followed by one dose of pVAX-TDM-Me (BCG-PVAX) or pVAXapa-TDM-Me (BCG-APA) administered i.m. after 30 days. Thirty days after vaccination, the mice were challenged intratracheally with a virulent strain of *M. tuberculosis* (1 × 10⁵ CFU). At 30 (A) or 70 (B) days after infection, the lungs were fixed in buffered formalin and stained with hematoxylin and eosin. Representative images of histological sections of lung lobes are shown for the PBS (A and B), TB (C and D), BCG (E and F), BCG-PVAX (G and H), and BCG-APA (I and J) groups. White and black arrows in the insets (TB group) indicate giant cells and xanthomatous macrophages, respectively. Arrows indicate congestion of blood vessels, and arrowheads indicate collapsed pulmonary alveoli. Original magnification, ×100. Magnification of the insets, ×400. The results shown are representative of 3 independent experiments.
group showed that consistent cellular and humoral responses generated by vaccination do not prevent the development of pulmonary injury in immunized mice (27). In contrast to those results, our results in this study showed that the most significant reduction in bacterial load of the lungs was associated with an important reduction of tissue injury in mice vaccinated using the BCG-APA strategy, 30 and 70 days after infection, compared with controls and BCG-vaccinated mice alone.

The advantageous properties of the microsphere-based delivery system likely account for the superior protection obtained in this study compared to that seen in previous studies. Most importantly, significant protection was accomplished by a boosting immunization with only one dose of pVAXapa-TDM-Me. Indeed, delivery systems such as antigen-encapsulated microspheres enhance the binding, uptake, and half-life of antigens (41), leading to a reduction in the number of doses in the immunization schedule (23). The slow degradation of such a delivery system allows sustained delivery of the antigen. All these data could explain the high level of protection conferred by this formulation compared to the other formulations that used only naked apa DNA (18, 34). Moreover, biodegradable PLGA microspheres have a proven safety record and an established utility in marketed products for controlled delivery of several peptide drugs (42). In this context, the combination of microspheres and the TDM adjuvant, which has been described as a potent immunomodulator (22), is an interesting and potentially beneficial approach to improve vaccine formulations and provide long-lasting protection against TB (23, 43). However, the mechanism of enhanced protection conferred by pVAXapa-TDM-Me, as well as the mechanism of protection conferred by BCG itself, remains to be determined.

In conclusion, the improved protection conferred by the combination of BCG priming followed by a pVAXapa-TDM-Me boosting immunization (BCG-APA) provides evidence for the hypothesis that the efficacy of BCG vaccination can be improved by subsequent boosting with a DNA vaccine. Further investigation on this topic is warranted.

ACKNOWLEDGMENTS
We thank Eliane N. Miyage, Butantan Institute, São Paulo, Brazil, for technical assistance in the gene expression studies. We also thank Elizabeth Albuquerque, Fiocruz, for helpful discussions on statistical analysis. We are grateful to Marcos de Almeida and Francisco Carvalho from the Pathology Service, IPEC-Fiocruz, for their technical assistance in histological sections.

This study was supported by grants from Fiocruz, Rio de Janeiro, Brazil (C.H.), and USP, Ribeirão Preto, São Paulo, Brazil (V.L.D.B.).

REFERENCES
1. World Health Organization. 2011. Global tuberculosis control: a short update to the 2011 report. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2009. Global tuberculosis control. Epidemiology, strategy, financing. World Health Organization, Geneva, Switzerland.
3. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, Efê S, Staveley I, Ewer K, Lalvani A. 2005. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366:1443–1451.
4. Sadoff JC. 2005. Vaccine risk and benefit in the developing world. Health Aff. (Millwood) 24:1379–1380.
5. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173–1180.
6. Kaufmann SH. 2005. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26:660–667.
7. Romano M, Huysgen K. 2009. DNA vaccines against mycobacterial diseases. Expert Rev. Vaccines 8:1237–1250.
8. Hubbard RD, Flory CM, Collins FM, Cocito C. 1992. Immunization of mice with the antigen A60 of Mycobacterium bovis BCG. Clin. Exp. Immunol. 88:129–131.
9. Andersen P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536–2544.
10. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ,
Belisle JT, Orme IM. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate proteins of Mycobacterium tuberculosis. Immunology 85:502–508.

11. Pal PG, Horwitz MA. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4791–4792.

12. Horwitz MA, Lee BW, Dillon BJ, Harth G. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:1530–1534.

13. Verreck FA, Verrenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werf NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW. 2001. MySA boosting of BCG and an attenuated, pHPD deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4:e5264. doi:10.1371/journal.pone.0005264.

14. Laqueyrerie A, Milizter P, Romain M, Fritsch EF, Maniatis T. 2001. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate proteins of Mycobacterium tuberculosis. Immunology 85:502–508.

15. Horwitz MA, Lee BW, Dillon BJ, Harth G. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:1530–1534.

16. Verreck FA, Verrenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werf NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW. 2001. MySA boosting of BCG and an attenuated, pHPD deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4:e5264. doi:10.1371/journal.pone.0005264.

17. Laqueyrerie A, Milizter P, Romain M, Fritsch EF, Maniatis T. 2001. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate proteins of Mycobacterium tuberculosis. Immunology 85:502–508.

18. Wang D, Robinson DR, Kwon GS, Samuel J. 2003. Single dose of a vaccine based on DNA encoding mycobacterial proteins hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect. Immun. 71:4441–4444.

19. Romano M, D’Souza S, Adnet PY, Laali R, Jurion F, Pfaller K, Huygen K. 2006. Priming but not boosting with plasmid DNA encoding mycolyltransferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24:e3353–e3364.

20. Ferraz JC, Stavropoulos E, Yang M, Coade S, Espitia C, Lowrie DB, Colston MJ, Tacson RE. 2004. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens protects improvement against tuberculosis in mice. Infect. Immun. 72:6945–6950.

21. Sable SB, Chervu M, Nanadakumar S, Sharma S, Bandopadhyay K, Kellar KL, Posey JE, Pilaytis BB, Amara RR, Shimmick TM. 2011. Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One 6(7):e22718. doi:10.1371/journal.pone.0022718.

22. Taylor JL, Turner OC, Basarab RJ, Belisle JT, Huygen K, Orme IM. 2003. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71:2192–2198.

23. Taylor JL, Ordway DJ, Troudt J, Gonzalez-Juarrero M, Basarab RJ, Orme IM. 2005. Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with Hsp65 DNA. Infect. Immun. 73:5189–5193.

24. Kini G, Cao T, Zhou Z, Zhang Y, Shi C, Chen Z, Chen L, Cai C, Fan X, 2011. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin. Dev. Immunol. 2011: 617892. doi:10.1155/2011/617892.

25. Moreno-Mendieta SA, Rocha-Zaaveta L, Rodriguez-Sandoja R. 2010. Adjuvants in tuberculosis vaccine development. FEMS Microbiol. Med. Microbiol. 58:75–84.

26. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57:391–410.

27. de Paula L, Silva CL, Carlos D, Matias-Peres C, Sorgi CA, Soares EG, Souza PR, Blades CR, Galletti FC, Bonato VL, Goncalves ED, Silva EV, Faccioli LH. 2007. Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs. Genet. Vaccines Ther. 5:2.